Amgen's Vectibix wins expanded colorectal cancer indications in Europe
This article was originally published in Scrip
Amgen has won the European Commission's blessing to market the firm's anti-epidermal growth factor receptor (EGFR) inhibitor Vectibix (panitumumab) in the European Union for the expanded indications of treating patients with wild-type KRAS metastatic colorectal cancer (mCRC) as a first-line therapy in combination with FOLFOX (folinic acid, fluorouracil and oxaliplatin) and as a second-line treatment in combination with FOLFIRI (fololinic acid, fluorouracil and irinotecan) in patients who have received first-line fluoropyrimidine-based chemotherapy, excluding irinotecan.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.